• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconGlaxoSmithKline

GlaxoSmithKline

Page 2 of 5
NewslettersFemale CEOs run 7% of companies on the Fortune 500 Europe, from H&M to Chanel
By Emma Hinchliffe and Joey AbramsNovember 9, 2023
LeadershipGSK’s CEO says you need thick skin if you’re going to step into the C-suite
By Fortune EditorsMay 31, 2023
Cityscape mixed with green plants, multi layered image
NewslettersBeing ‘nature-positive’ has been a hollow aim. That’s about to change
By Peter VanhamMay 25, 2023
FinanceThe world’s 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021
By Paige McGlauflinAugust 15, 2022
US-HEALTH-VIRUS-TREATMENT
HealthGSK says its COVID antibody therapy works against Omicron. Here’s what other drugmakers say about their treatments
By Sophie MellorDecember 7, 2021
In this photo illustration the Covax Facility logo seen displayed on a smartphone screen with the logo of CureVac in the background.
HealthCureVac scraps its first-generation COVID-19 vaccine candidate, shares tumble
By David MeyerOctober 12, 2021
HealthGlaxo reaches $2.2 billion deal with Alector to develop drug targeting Alzheimer’s, Parkinson’s
By Suzi Ring and BloombergJuly 2, 2021
An employee checks bottles of diluent inside the pharmaceutical plant Fareva in Poce-sur-Cisse, Central France, on April 22, 2021. Fareva was chosen as the main supplier of the candidate RNA messenger vaccine from the German company CureVac. The site will therefore produce the diluent used in this vaccine.
HealthThese four COVID-19 vaccines could soon join the pandemic fight
By David MeyerMay 8, 2021
LeadershipGlaxoSmithKline gets rid of Trump’s vaccine adviser Slaoui for sexual harassment
By James Paton, Riley Griffin and BloombergMarch 24, 2021
HealthPromising COVID-19 antibody therapy significantly reduces risk of hospitalization, death
By Suzi Ring and BloombergMarch 12, 2021
HealthSanofi and GSK to restart trial of COVID-19 vaccine after delay
By Tim Loh, Suzi Ring and BloombergFebruary 22, 2021
In this photo illustration various medical syringes seen with Sanofi Pasteur company logo displayed on a screen in the background.
HealthGSK and Sanofi shares fall as the pharma giants delay COVID-19 vaccine until late 2021
By David MeyerDecember 11, 2020
NewslettersSanofi, GlaxoSmithKline reach multi-billion dollar deal with U.S. for coronavirus vaccine
By Sy MukherjeeJuly 31, 2020
HealthU.S. pledges $2.1 billion for up to 600 million doses of Sanofi, GlaxoSmithKline vaccine
By James Paton and BloombergJuly 31, 2020
Sanofi will combine its experimental coronavirus vaccine with GlaxoSmithKline Plc’s adjuvant technology, which may allow more doses of a shot to be produced.
HealthSanofi and GlaxoSmithKline are teaming up to develop a coronavirus vaccine
By James Paton, Suzi Ring and BloombergApril 14, 2020
1
  • 1
  • 2
  • 3
  • 4
  • 5
5
Most Popular
Success
After decades in the music industry, Pharrell Williams admits he never stops working: ‘If you do what you love everyday, you’ll get paid for free'An image of a popular article
By Emma BurleighFebruary 3, 2026
Politics
Peter Thiel warns the Antichrist and apocalypse are linked to the ‘end of modernity’ currently happening—and cites Greta Thunberg as a driving exampleAn image of a popular article
By Nick LichtenbergFebruary 4, 2026
Investing
Ray Dalio warns the world is ‘on the brink’ of a capital war of weaponizing money—and gold is the best way for people to protect themselvesAn image of a popular article
By Sasha RogelbergFebruary 4, 2026
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.